title: [Pediatric hemato-oncology: from cellular biology to individualized targeted therapies].
abstract: Progresses in pediatric oncology over the last decades have been dramatic and allow current cure rates above 80%. There are mainly due to multicentre clinical trials aiming at optimizing chemotherapy protocols as well as local therapies in a stepwise approach. Most of the new anticancer drugs currently in development are based on targeted therapies, directed to specific targets present only in or on tumor cells, like growth factor receptors, mechanisms involved in proliferation, DNA repair, apoptosis, tumor invasion or angiogenesis. Concerning bone marrow transplantation also, new strategic approaches are in advanced development. They aim at reducing treatment induced toxicity and enhancing efficacy at the same time. This short paper would like to point out these new technologies, which should be known by the general practitioner.
authors.affiliation: Unité d'hémato-oncologie pédiatrique, DMCP, CHUV, 1011 Lausanne. nicolas.von-der-weid@chuv.ch
authors.forename: Nicolas-Xavier
authors.initials: NX
authors.lastname: von der Weid
authors.forename: Marc
authors.initials: M
authors.lastname: Ansari
mesh_terms: D002648:Child; D019337:Hematologic Neoplasms / Q000188:drug therapy* / Q000601:surgery*; D006801:Humans; D058990:Molecular Targeted Therapy; D033581:Stem Cell Transplantation